ALTANA opens Research Institute in the U.S.
"This biotech research institute has established us in the especially creative Boston environment with its many qualified scientists and researchers, and is an important step in establishing our fully integrated U.S. organization. The institute will function as an interface with our Discovery Research unit in Constance, helping us to find new therapeutic approaches in our core research fields, i.e. gastroenterology, respiratory and oncology", commented Professor Dr. Heinz W. Radtke, Member of the Management Board and Head of Research and Development at ALTANA Pharma AG, at the official opening ceremony.
Around 50 scientists are currently working on the various ARI research projects under the leadership of Dr. Klaus Melchers, the ARI's Vice President and Chief Operating Officer. Work on the ARI began in November 2001 as part of a 5 ½-year collaboration between ALTANA Pharma and GPC Biotech. ALTANA will invest a total of around US $ 120 million in the institute within the framework of this partnership.
In recent years, ALTANA Pharma has increased its R&D budget by around 30% annually. In the 2002 financial year, the company invested EUR 335 million in Research & Development, which is equivalent to around 20% of therapeutics sales. The R&D budget will again be expanded in 2003 to further enhance ALTANA Pharma's long-term innovative capacity.
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.